

Contents

Part I Rationale and Safety for BoNT

1. Safety and General Principles of Botulinum Toxin Therapies:	
Pearls From Across Medical Fields	3
1.1 Introduction	3
1.2 Considerations for the Safe Use of BoNT	3
1.3 General Principles of Botulinum Toxin Therapy	6
1.4 After BoNT Injection Patient Management Principles	7
1.5 Storage and Dilution of Botulinum Toxins	8
1.5.1 OnabotulinumtoxinA (BOTOX®)	8
1.5.2 AbobotulinumtoxinA (Dysport®)	9
1.5.3 RimabotulinumtoxinB (Myobloc and Neurobloc®)	10
1.5.4 IncobotulinumtoxinA (Xeomin®)	10
1.6 Issues in Multi-specialty Interactions	10
1.7 Conclusions	11
Reference	11
2. Biology and Mechanism of Action	13
2.1 Introduction	13
2.2 History of Medical Botulinum Toxin	13
2.3 Seven Serotypes of Botulinum Toxin	14
2.4 Pathophysiology	15
2.4.1 Four Required Steps to Induce Paralysis	15
2.5 BoNT Effect on Muscle Neurotransmission	17
2.6 BoNT Action at Synapses and on Neuropeptides	18
2.7 BoNT Action on Urinary Tract Striated and Smooth Muscles	18
2.7.1 Efferent Effect	19
2.7.2 Afferent Effect	20
2.7.3 Effects on Acetylcholine and ATP Release	20
2.7.4 Effect on Hot and Cold Sensitive Sensory Receptors	21
2.7.5 Clinical Effects on Calcitonin Gene-Related Peptide and Substance P Release	21
2.7.6 Inhibition of Nerve Growth Factor Release and Receptor Transport	22

2.8 Histological Impact of BoNT Injection	22
2.9 BoNT Antibody Production	23
2.10 Conclusion	24
References	25

Part II Bladder

3. Botulinum Toxin for Neurogenic Detrusor Overactivity	29
3.1 Introduction	29
3.2 Indications	29
3.2.1 Spinal Cord Injury	30
3.2.2 Multiple Sclerosis: Variable Spectrum and Disease Progression.	31
3.2.3 Pediatric Neurogenic Bladders.	32
3.2.4 Parkinson's Disease and Multisystem Atrophy	32
3.3 What Is the Work-Up?	32
3.3.1 History and Physical Examination.	32
3.3.2 Urodynamic Evaluation	33
3.4 How to Do It.	33
3.4.1 Patient Preparation	33
3.4.2 Cystoscope	36
3.4.3 Botulinum Toxin Reconstitution	37
3.4.4 Dose	38
3.4.5 Depth, Location, and Amount of Injection.	38
3.4.6 Injection Technique	39
3.4.7 Simultaneous Bladder and Sphincter BoNT Injection.	41
3.4.8 Post-procedure and Follow-Up.	42
3.4.9 How Long Does It Last and When Is Botulinum Toxin Injection Repeated	42
3.4.10 Subsequent Dose Selection (Can You and Should You Go Up or Down on Dose).	43
3.4.11 Risk of Antibody Formation	43
3.5 What Are the Results	44
3.5.1 Clinical Studies	44
3.5.2 Duration of Effect	47
3.5.3 Repeat Injections	47
3.5.4 No Histological Damage to Bladder with BoNT Repeated Injections	49
3.5.5 Can BoNT Improve Bladder Compliance?	49
3.5.6 Adverse Events.	52
3.5.7 Simultaneous Bladder and Sphincter BoNT Injection.	55
3.6 Future Perspective: Electrical Neuromodulation and Stem Cell Research	56
3.7 Conclusions	57
References	57

4. Overactive Bladder and Idiopathic Detrusor Overactivity	61
4.1 Introduction	61
4.2 Rationale for BoNT Use in Idiopathic OAB	61
4.3 How to Do It	62
4.3.1 Simplified Delivery Using Flexible Cystoscope	62
4.3.2 Depth of Injection	64
4.4 What Are the Results?	68
4.4.1 Botulinum Toxin Type A	68
4.4.2 Botulinum Toxin Type B	70
4.4.3 Predictors of Poor Response	71
4.5 Side Effects	72
4.5.1 Risk-Benefit Ratio	73
4.6 Conclusions	76
References	76
5. BoNT for Bladder and Pelvic Pain	79
5.1 Introduction	79
5.2 Indications	79
5.3 What Is the Work-Up	80
5.3.1 History and Physical Examination	80
5.3.2 Urodynamic Evaluation	80
5.4 How to Do It	81
5.4.1 Patient Preparation	81
5.4.2 Cystoscope	81
5.4.3 Botulinum Toxin Reconstitution	83
5.4.4 Dose	83
5.4.5 Depth, Location, and Amount of Injection	84
5.4.6 Injection Technique	84
5.4.7 Post-procedure and Follow-Up	85
5.4.8 How Long Does It Last and When Is Botulinum Toxin Injection Repeated	85
5.5 What Are the Results	85
5.5.1 Clinical Results IC/PBS	85
5.5.2 Chronic Female Pelvic Pain Syndromes	89
5.5.3 Chronic Prostatitis/Male Chronic Pelvic Pain Syndrome (CP/CPPS)	90
5.5.4 Radiation and Inflammatory Cystitis	90
5.6 Conclusions	91
References	92
6. Pediatric Botulinum Toxin Applications	95
6.1 Introduction	95
6.2 Indications	96
6.2.1 When to Consider Botulinum Toxin Injection	96
6.2.2 Nonneurogenic Indications in Children	97
6.3 What Is the Work-Up?	97

6.3.1	History and Physical Examination	97
6.3.2	Urodynamic Evaluation	97
6.4	How to Do It.	98
6.4.1	Cystoscope	98
6.4.2	Botulinum Toxin Reconstitution	99
6.4.3	Dose	99
6.4.4	Depth, Location, and Amount of Injection	100
6.4.5	Injection Technique	100
6.4.6	Post-procedure and Follow-up	101
6.5	What Are the Results?	101
6.5.1	Idiopathic Detrusor Overactivity Clinical Studies	104
6.5.2	Voiding Dysfunction Clinical Studies	105
6.5.3	Repeat Injection	106
6.6	Conclusions	106
	References	107

Part III Prostate and Pelvic Floor

7.	Botulinum Toxin Injection for Prostate Disorders	111
7.1	Introduction	111
7.2	Prostate BoNT Rationale and Mechanism of Action.	113
7.3	Indications	115
7.3.1	BPH	115
7.3.2	Prostatitis/Prostatodynia	116
7.4	What Is the Work-up?	116
7.4.1	History and Physical Examination.	116
7.5	How to Do It.	117
7.5.1	BPH	117
7.5.2	Prostatitis/Prostatodynia	121
7.6	What Are the Results?	121
7.6.1	BPH	123
7.6.2	Prostatitis/Prostatodynia	126
7.6.3	Adverse Events.	127
7.7	Conclusions	128
	References	128
8.	Sphincter and Pelvic Floor Disorders Applications	131
8.1	Introduction	131
8.1.1	Detrusor-Sphincter Dyssynergia Pathology.	131
8.2	Indications	132
8.2.1	Neurogenic DSD	132
8.2.2	Non-neurogenic DSD.	133
8.2.3	Pelvic Floor and Pain.	134
8.3	What Is the Work-Up.	134
8.3.1	History and Physical Examination.	134
8.3.2	Urodynamic Evaluation	134

8.4	How to Do It	137
8.4.1	Neurogenic DSD	137
8.4.2	Simultaneous Bladder and Sphincter BoNT Injection.	138
8.4.3	Non-neurogenic DSD.	138
8.4.4	Pelvic Floor and Pain	139
8.5	What Are the Results	141
8.5.1	Neurogenic DSD	142
8.5.2	Adverse Events.	144
8.5.3	Simultaneous Bladder and Sphincter BoNT Injection.	145
8.5.4	Non-neurogenic DSD.	145
8.5.5	Post-surgical Retention	146
8.5.6	Bladder Neck Dyssynergia (Primary Bladder Neck Obstruction)	147
8.5.7	Pelvic Floor and Pain	147
8.5.8	Pain Due to Hypertonic Pelvic Floor Muscles.	148
8.5.9	Vulvodynia.	149
8.5.10	Chronic Prostatitis/Male Chronic Pelvic Pain Syndrome	149
8.6	Conclusion	150
	References	150

Part VI Role of BoNT in Medicine

9.	Non-urological Uses of Toxin with Genitourinary Insight	155
9.1	Introduction	155
9.2	BoNT in Pain Syndromes	155
9.2.1	Back Pain	155
9.2.2	Myofascial Pain Syndromes.	156
9.2.3	Headache and Migraine	158
9.3	BoNT in the Gastrointestinal Tract	159
9.3.1	Achalasia	160
9.3.2	Chronic Anal Fissure	161
9.3.3	Emerging Gastrointestinal Uses of BoNT Therapy	162
9.4	BoNT for Hyperhidrosis	163
9.4.1	Therapeutic Approaches for Hyperhidrosis.	163
9.4.2	The Role of BoNT in Hyperhidrosis Treatment	163
9.4.3	Clinical Studies of BoNT: Axillary Hyperhidrosis	164
9.4.4	Clinical Studies of BoNT: Palmar Hyperhidrosis	165
9.4.5	BoNT for Drooling.	165
9.5	Conclusions	166
	References	166
10.	Health Economics of Botulinum Toxin Application	169
10.1	Introduction	169
10.2	Sacral Nerve Neuromodulation	169
10.2.1	Clinical Results with Sacral Nerve Neuromodulation	170

10.3	Comparative Cost Analysis	170
10.3.1	Results	170
10.4	Other Recent Reports	172
10.4.1	BoNT Versus Anticholinergics	172
10.4.2	BoNT Versus Augmentation Cystoplasty	172
10.4.3	Different Brands of Botulinum Toxin	173
10.4.4	BoNT Cost to the French Health Care System	173
10.4.5	BoNT Versus New Modalities	174
10.5	Conclusion.	174
	References	175
11.	Perspectives from Around the World: Panorama of Where We Are and Where We Are Going	177
11.1	Australia: Jeffrey Thavaseelan	177
11.2	Belgium: Dirk De Ridder	178
11.3	Canada: Sender Herschorn	179
11.4	France: Emmanuel Chartier-Kastler	180
11.5	Germany: Tim Schneider	181
11.6	Indian: Sanjay Pandey.	181
11.6.1	Early Years of BoNT in Indian Urology (2005–2007)	181
11.6.2	The BoNT “Wonder Years” in Indian Urology (2008–2010).	182
11.6.3	Challenges and Drafts for Future (2011 – Beyond).	183
11.7	Italy: Antonella Giannantoni.	183
11.8	Japan: Yukio Homma	184
11.9	Korea: Kyu-Sung Lee	185
11.10	The Netherlands: John Heesakkers.	186
11.11	Portugal: Francisco Cruz.	187
11.12	Singapore: Michael Wong.	188
11.13	Taiwan: Alex T.L. Lin.	189
11.14	United Kingdom: Arun Sahai and Prokar Dasgupta.	190
11.15	United Kingdom Urogynaecology: Anga S. Arunkalaivanan	191
	References	192
	Appendix 1	195
	Appendix 2	199
	Appendix 3	201
	Index	205